Advertisement

Endoscopy in the Management of Inflammatory Bowel Disease: Who, When, and How

  • Yasuo SuzukiEmail author
Chapter

Abstract

In inflammatory bowel disease (IBD), confirmation of mucosal healing by endoscope has been recommended as a gold standard for complete remission.

In ulcerative colitis (UC), colonoscopic examination has been thought to be the most reliable approach to view all parts of the large intestine. Detecting the disease type of UC accurately by total colonoscope examination is very important, therefore a total colonoscope examination must be done at the time of diagnosis and starting induction therapy. And a surveillance program to detect dysplasia or early-stage colon cancer by diligent colonoscopic surveillance has been emphasized in UC.

In Crohn’s disease (CD) the diagnostic relevance of endoscopy remains unclear as compared with its established value in UC. CD lesions may appear at any site from the mouth to the perianal region; therefore, thorough examination from the upper parts of digestive track to the rectum should be examined by endoscope, including the small intestine being examined by capsule endoscopy or balloon endoscopy. The confirming of mucosal healing of involved CD lesion by endoscope examination is now strongly recommended because the achievement of mucosal healing of the involved lesion affects significantly the long-term prognosis at the stage of clinical remission after treatment.

Keywords

Inflammatory bowel disease Ulcerative colitis Crohn’s disease Endoscopy Mucosal healing 

References

  1. 1.
    Froslie KF, et al. Gastroenterology. 2007;133(2):412–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Neurath MF, Travis SPL. Gut. 2012;61:1619–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov;145(5):987–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Taghvaei T, Maleki I, Nagshvar F, et al. Intern Emerg Med. 2014;10:321.CrossRefPubMedGoogle Scholar
  5. 5.
    Emanuel B, et al. Dig Dis Sci. 2014;60:485.Google Scholar
  6. 6.
    Nakarai A, Kato J, Hiraoka S, et al. Am J Gastroenterol. 2013;108:83–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rubin CE, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103(5):1611–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Watanabe T, AjiokaY. Matsumoto T, et al. Target biopsy or step biopsy ? Optimal surveillance for ulcerative colitis: a Japanease nationwide randomized controlled trial. L Gastroenterol 2011;46:11-16Google Scholar
  11. 11.
    Takenaka K, Ohtsuka K, Kitazume Y, et al. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology. 2014 Aug;147(2):334–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–63.CrossRefPubMedGoogle Scholar
  13. 13.
    De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015;385:1406–17.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2018

Authors and Affiliations

  1. 1.Internal Medicine, Sakura Medical CenterToho UniversityChibaJapan

Personalised recommendations